Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma

Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma

Abstract Glioblastoma (GBM) is the most aggressive type of primary brain tumours. Anti-angiogenic therapies (AAT), such as bevacizumab, have been developed to target the tumour blood supply. However, GBM presents mechanisms of escape from AAT activity, including a speculated direct effect of AAT on...

Full description

Bibliographic Details
Main Authors: Thomas Simon, Sotiria Pinioti, Pascale Schellenberger, Vinothini Rajeeve, Franz Wendler, Pedro R. Cutillas, Alice King, Justin Stebbing, Georgios Giamas
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Molecular Cancer
Subjects:
Bevacizumab
Extracellular vesicles
Glioblastoma
Resistance
Online Access:http://link.springer.com/article/10.1186/s12943-018-0878-x

Internet

http://link.springer.com/article/10.1186/s12943-018-0878-x

Similar Items